- Home
- IRWD
as 07-26-2024 4:00pm EST
Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 926.7M | IPO Year: | 2010 |
| Target Price: | $17.75 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.47 - $15.70 | Next Earning Date: | 08-06-2024 |
| Revenue: | $413,551,000 | Revenue Growth: | -0.86% |
| Revenue Growth (this year): | -5.53% | Revenue Growth (next year): | 13.28% |
Stock Insider Trading Activity of Ironwood Pharmaceuticals Inc. (IRWD)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Moukheibir Catherine | IRWD | Director | Jun 6 '24 | Sell | $6.61 | 35,574 | $235,144.14 | 48,633 | SEC Form 4 |
| Moukheibir Catherine | IRWD | Director | Jun 6 '24 | Sell | $6.36 | 44,426 | $282,549.36 | 84,207 | SEC Form 4 |
| Davis Andrew | IRWD | SVP, Chief Business Officer | May 20 '24 | Sell | $6.45 | 22,725 | $146,576.25 | 288,031 | SEC Form 4 |
| MCCOURT Thomas A | IRWD | Chief Executive Officer | May 20 '24 | Sell | $6.45 | 67,618 | $436,136.10 | 1,150,330 | SEC Form 4 |
| Shetzline Michael | IRWD | CMO,SVP,Head-Res&Drug | May 20 '24 | Sell | $6.45 | 16,128 | $104,025.60 | 413,719 | SEC Form 4 |
| John Minardo | IRWD | Chief Legal Officer | May 20 '24 | Sell | $6.45 | 17,404 | $112,255.80 | 294,571 | SEC Form 4 |
| Duane Jon R | IRWD | Director | Mar 6 '24 | Buy | $8.70 | 6,920 | $60,204.00 | 121,028 | SEC Form 4 |
| Emany Sravan Kumar | IRWD | SVP, Chief Financial Officer | Mar 4 '24 | Buy | $9.38 | 10,684 | $100,215.92 | 301,733 | SEC Form 4 |
| John Minardo | IRWD | Chief Legal Officer | Feb 12 '24 | Sell | $15.24 | 47,380 | $722,071.20 | 224,796 | SEC Form 4 |
| Shetzline Michael | IRWD | CMO,SVP,Head-Res&Drug | Feb 12 '24 | Sell | $15.24 | 38,618 | $588,538.32 | 340,484 | SEC Form 4 |
| Silver Ronald | IRWD | Principal Accounting Officer | Feb 12 '24 | Sell | $15.24 | 7,908 | $120,517.92 | 134,264 | SEC Form 4 |
| Davis Andrew | IRWD | SVP, Chief Business Officer | Feb 12 '24 | Sell | $15.24 | 9,846 | $150,053.04 | 208,324 | SEC Form 4 |
| MCCOURT Thomas A | IRWD | Chief Executive Officer | Feb 12 '24 | Sell | $15.24 | 177,164 | $2,699,979.36 | 832,774 | SEC Form 4 |
| Kessler Marla L | IRWD | Director | Dec 14 '23 | Sell | $11.19 | 9,926 | $111,071.94 | 96,572 | SEC Form 4 |
| Davis Andrew | IRWD | SVP, Chief Business Officer | Nov 20 '23 | Sell | $9.69 | 3,287 | $31,851.03 | 217,374 | SEC Form 4 |
Latest Ironwood Pharmaceuticals Inc. News
IRWD Breaking Stock News: Dive into IRWD Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call
Argus Research
3 days ago
IRWD: Lowering target price to $5.00
Zacks
9 days ago
Implied Volatility Surging for Ironwood Pharmaceuticals (IRWD) Stock Options
Argus Research
10 days ago
IRWD: Raising target price to $6.00
Argus Research
17 days ago
IRWD: What does Argus have to say about IRWD?
Argus Research
24 days ago
IRWD: Lowering target price to $5.00
MT Newswires
a month ago
Ironwood Pharmaceuticals Names Sravan Emany to Additional Role of Chief Operating Officer
GuruFocus.com
a month ago
Insider Sale: Director Julie Mchugh Sells Shares of Ironwood Pharmaceuticals Inc (IRWD)
Compare IRWD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IRWD Ironwood Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.